141st APHA Annual Meeting

In This section

285840
Eeoicpa claims and the impairment rating process

Wednesday, November 6, 2013

Karen Mulloy, DO, MSCH , Mountain and Plains Education and Research Center, Colorado School of Public Health, Aurora, CO
BACKGROUND. The Energy Employees Occupational Illness Compensation Program (EEOICPA), a federally mandated program, provides compensation to eligible employees and former employees of the Department of Energy, its contractors and subcontractors, and survivors and certain beneficiaries of Section five of the Radiation Exposure Compensation Act (RECA).

METHODS: Eligible workers who develop an illness as a result of toxic exposures, such as chemicals, acids, heavy metals, solvents, under Part E receive compensation and payment of medical expenses. Under Part E benefits are determined by wage loss, impairment, and survivorship.

RESULTS AND CONCLUSIONS. The impairment rating process for eligible workers has been limited by physicians who are unwilling or unfamiliar with the process to complete the impairment rating for their patients. Several cases will be reviewed to analyze lessons learned from the Part E impairment rating process. Recommendations will be made on how to increase access for workers to physicians to complete the impairment rating.

Learning Areas:
Occupational health and safety
Public health or related laws, regulations, standards, or guidelines
Public health or related public policy

Learning Objectives:
Describe components of the Energy Employees Occupational Illness Compensation Program; Analyze lessons learned from cases of former workers applying for Part E; Identify strategies for increasing physician involvement in the EEOICPA program impairment rating process.

Keywords: Workers' Compensation, Occupational Disease

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Long experience in clinical occupational medicine for former DOE workers.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.